过度收缩性表型在过度缩性心肌病中表明不良的血液动力学,冠状动脉流和预后
Karina Wierzbowska-Drabik1, Eszter Dalma Pálinkás2, Maria Grazia D'Alfonso3
1Department of Internal Diseases and Clinical Pharmacology, Medical University of Lodz, ul. Kniaziewicza 1/5, 91-347 Lodz, Poland.
European heart journal. Cardiovascular Imaging
|August 29, 2025
概括
在高性心肌病 (HCM) 中,左心室超收缩表型 (HP) 与心脏功能低下和长期存活率降低有关.
科学领域:
- 心脏病学
- 心血管生理学
- 心声检查
背景情况:
- 缩性心肌病是一种复杂的遗传性心脏病.
- 左心室 (LV) 超收缩性表型 (HP) 在HCM中的临床和预后意义尚不清楚.
- 在HCM患者中常见的是保存的射出分数 (EF),但结果可能有所不同.
研究的目的:
- 评估 LV 超收缩性表型 (HP) 在缩性心肌病 (HCM) 中的临床和预后意义.
- 为了研究与HP相关的血液动力学概况和长期存活率.
主要方法:
- 1533名高血压患者的EF≥50%接受了胸前心声扫描 (TTE).
- 计算了静脉压力 (静脉压+LVOTG/ESV),并将HP定义为最高四分位数 (> 7. 32 mmHg/ ml).
- 对 1200 名患者进行了生存分析,并提供了随访数据.
主要成果:
- HP患者心率较高,中风体积较小,左心室体积指数较大,冠状动脉流速增加.
- 输出力与输出力EF有中等相关性,与输出力流通道梯度 (LVOTG) 有弱相关性.
- 强度> 7. 32 mmHg/ mL独立地与任何原因死亡的风险增加1. 44倍 (HR1. 44;95% CI 1. 00- 2.07).
结论:
- 在HCM中,LV超收缩型表型 (HP) 与不良的全身,心脏和冠状动力学特征有关.
- HCM患者的HP与长期存活率显著降低有关.
- 这些发现突显了在HCM管理中评估LV力的预后重要性.
相关概念视频
Cardiomyopathy III: Hypertrophic Cardiomyopathy
45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45
Heart Failure II: Pathophysiology
37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37
Cardiomyopathy V: Interprofessional Care
32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
Imbalances in Cardiac Output
1.5K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.5K
Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Cardiomyopathy II: Dilated Cardiomyopathy
21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21


